{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:00:29Z","timestamp":1794369629143,"version":"4.9.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.clinthera.2025.06.012","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T11:22:30Z","timestamp":1752578550000},"page":"e1-e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effect of Intravenous Immunoglobulin or Plasmapheresis in Myasthenic Crisis and Worsening Myasthenia Gravis Compared to Without Rescue Treatment"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6141-3592","authenticated-orcid":false,"given":"Jayantee","family":"Kalita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagendra B.","family":"Gutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faim","family":"Ahamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopali","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.06.012_bib0001","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3233\/JND-140045","article-title":"The epidemiology of neuromuscular disorders: a comprehensive overview of the literature","volume":"2","author":"Deenen","year":"2015","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0002","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1590\/0004-282X20130108","article-title":"The myasthenic patient in crisis: an update of the management in Neurointensive Care Unit","volume":"71","author":"Godoy","year":"2013","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0003","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/ene.12703","article-title":"Myasthenia gravis: descriptive analysis of life-threatening events in a recent nationwide registry","volume":"22","author":"Ramos-Fransi","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0004","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1055\/s-0036-1592106","article-title":"Getting rid of weakness in the ICU: an updated approach to the acute management of myasthenia gravis and Guillain-Barr\u00e9 syndrome","volume":"36","author":"Lizarraga","year":"2016","journal-title":"Semin Neurol"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0005","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/00003246-199707000-00027","article-title":"Therapy of myasthenic crisis","volume":"25","author":"Berrouschot","year":"1997","journal-title":"Crit Care Med"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0006","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","article-title":"Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases","volume":"94","author":"Neumann","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0007","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.nmd.2021.08.008","article-title":"Predictors of outcome in patients with myasthenic crisis undergoing non-invasive mechanical ventilation: a retrospective 20 year longitudinal cohort study from a single Italian center","volume":"31","author":"Iori","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0008","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1749-6632.1981.tb33765.x","article-title":"Aspects of the natural history of myasthenia gravis: crisis and death","volume":"377","author":"Cohen","year":"1981","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0009","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/qjmed\/hcn152","article-title":"Myasthenic crisis","volume":"102","author":"Chaudhuri","year":"2009","journal-title":"QJM"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0010","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s10072-014-1659-y","article-title":"Predictors of outcome of myasthenic crisis","volume":"35","author":"Kalita","year":"2014","journal-title":"Neurol Sci"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0011","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/mus.26689","article-title":"Factors associated with acute exacerbations of myasthenia gravis","volume":"60","author":"Gummi","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0012","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of myasthenia gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurol Clin"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0013","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ana.410150615","article-title":"Azathioprine in the treatment of myasthenia gravis","volume":"15","author":"Witte","year":"1984","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0014","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/pgmj.66.772.102","article-title":"Long term treatment of myasthenia gravis with azathioprine","volume":"66","author":"Fonseca","year":"1990","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0015","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3390\/jcm11061597","article-title":"Current treatment of myasthenia gravis","volume":"11","author":"Alhaidar","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0016","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/nrneurol.2011.14","article-title":"Neuromuscular disease: acute treatment for myasthenia gravis","volume":"7","author":"Gilhus","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0017","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0022-510X(85)90173-X","article-title":"Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy","volume":"70","author":"Vermeulen","year":"1985","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0018","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barr\u00e9 syndrome. Dutch Guillain-Barr\u00e9 Study Group","volume":"326","author":"van der Mech\u00e9","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0019","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","volume":"2014","author":"Hughes","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1212868","article-title":"Lymphoplasmapheresis versus plasma exchange in severe myasthenia gravis: a retrospective cohort study","volume":"14","author":"Duan","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0021","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/bjh.12629","article-title":"The mechanisms of action of plasma exchange","volume":"164","author":"Reeves","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0022","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0023","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0024","first-page":"478","article-title":"Plasmapheresis or intravenous immunoglobulin for myasthenia gravis crisis in King Chulalongkorn Memorial Hospital","volume":"92","author":"Pittayanon","year":"2009","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0025","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1046\/j.1525-1594.2001.06717.x","article-title":"Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis","volume":"25","author":"R\u00f8nager","year":"2001","journal-title":"Artif Organs"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0026","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"12","author":"Gajdos","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0027","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/NRL.0000000000000026","article-title":"IVIG versus PLEX in the treatment of worsening myasthenia gravis: what is the evidence?: a critically appraised topic","volume":"19","author":"Dhawan","year":"2015","journal-title":"Neurologist"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0028","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/0028-3886.15050","article-title":"Myasthenic crisis: clinical features, complications and mortality","volume":"53","author":"Murthy","year":"2005","journal-title":"Neurol India"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0029","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.2147\/JIR.S455104","article-title":"Therapeutic plasma exchange in AChR-Ab positive generalized myasthenia gravis: a real world study about its early response","volume":"17","author":"Chen","year":"2024","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0030","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s12028-021-01259-4","article-title":"Acetylcholinesterase inhibitors in myasthenic crisis: a systematic review of observational studies","volume":"35","author":"Jr","year":"2021","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0031","series-title":"Clinical Neurophysiology: Nerve Conduction, Electromyography, Evoked Potentials","year":"2019"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0032","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.48.5.1253","article-title":"Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation","volume":"48","author":"Thomas","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0033","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00131402-200209000-00009","article-title":"On the concept of myasthenic crisis","volume":"4","author":"Bedlack","year":"2002","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0034","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0035","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.21883","article-title":"The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis","volume":"43","author":"Burns","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0036","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ncl.2018.01.006","article-title":"Measuring clinical treatment response in myasthenia gravis","volume":"36","author":"Barnett","year":"2018","journal-title":"Neurol Clin"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.662856","article-title":"Therapeutic plasma exchange in myasthenia gravis: a systematic literature review and meta-analysis of comparative evidence","volume":"12","author":"Ipe","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0038","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1212\/WNL.52.3.629","article-title":"Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis","volume":"52","author":"Qureshi","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0039","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00415-006-0235-7","article-title":"Comparative efficacy of low dose, daily versus alternate day plasma exchange in severe myasthenia gravis: a randomised trial","volume":"254","author":"Trikha","year":"2007","journal-title":"J Neurol"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109058","article-title":"Plasma exchange versus intravenous immunoglobulin in AChR subtype myasthenic crisis: a prospective cohort study","volume":"241","author":"Wang","year":"2022","journal-title":"Clin Immunol"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0041","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.3390\/biomedicines11123180","article-title":"Plasma exchange versus intravenous immunoglobulin in worsening myasthenia gravis: a systematic review and meta-analysis with special attention to faster relapse control","volume":"11","author":"Pavlekovics","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0042","first-page":"453","article-title":"Myasthenic crisis: a retrospective study","volume":"52","author":"Panda","year":"2004","journal-title":"Neurol India"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0043","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/08916934.2016.1214823","article-title":"Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis","volume":"49","author":"Guptill","year":"2016","journal-title":"Autoimmunity"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0044","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/archneur.63.7.930","article-title":"Plasma exchange in neuroimmunological disorders: part 1: rationale and treatment of inflammatory central nervous system disorders","volume":"63","author":"Lehmann","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0045","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0046","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0047","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2025.06.012_bib0048","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: Association of British Neurologists\u2019 management guidelines","volume":"15","author":"Sussman","year":"2015","journal-title":"Pract Neurol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T05:02:10Z","timestamp":1763787730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825002188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0149291825002188"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.06.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Intravenous Immunoglobulin or Plasmapheresis in Myasthenic Crisis and Worsening Myasthenia Gravis Compared to Without Rescue Treatment","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}